The stock of Anacor Pharmaceuticals Incorporated (NASDAQ:ANAC) registered an increase of 9.06% in short interest. ANAC’s total short interest was 5.08M shares in March as published by FINRA. Its up 9.06% from 4.66M shares, reported previously. With 1.34M shares average volume, it will take short sellers 4 days to cover their ANAC’s short positions. The short interest to Anacor Pharmaceuticals Incorporated’s float is 13.09%. The stock increased 5.07% or $2.88 on March 24, hitting $59.71. Anacor Pharmaceuticals Inc (NASDAQ:ANAC) has declined 54.69% since August 19, 2015 and is downtrending. It has underperformed by 52.59% the S&P500.
Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $2.81 billion. The Firm is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. It currently has negative earnings. The Company’s lead product candidate, AN2728 is an investigational non-steroidal topical PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis.
The institutional sentiment increased to 1.53 in 2015 Q3. Its up 0.12, from 1.41 in 2015Q2. The ratio improved, as 26 funds sold all Anacor Pharmaceuticals Inc shares owned while 61 reduced positions. 56 funds bought stakes while 77 increased positions. They now own 48.95 million shares or 30.28% more from 37.58 million shares in 2015Q2.
Rho Capital Partners Inc holds 41.75% of its portfolio in Anacor Pharmaceuticals Inc for 1.07 million shares. Vhcp Management Llc owns 1.18 million shares or 35.56% of their US portfolio. Moreover, Palo Alto Investors Llc has 14.6% invested in the company for 2.58 million shares. The New York-based Baker Bros. Advisors Lp has invested 4.5% in the stock. Apis Capital Advisors Llc, a New York-based fund reported 23,000 shares.
Out of 4 analysts covering Anacor Pharmaceuticals Inc. (NASDAQ:ANAC), 5 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Anacor Pharmaceuticals Inc. was the topic in 4 analyst reports since July 21, 2015 according to StockzIntelligence Inc. Mizuho initiated the stock on March 11 with “Buy” rating.
Anacor Pharmaceuticals Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.